LOB heads into Q3 earnings with shorts rebuilding and analysts trimming targets
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Live Oak Bancshares reports Q3 results on October 22 with a week's worth of analyst target cuts behind it and short interest at a one-month high, a setup that puts the earnings print under more scrutiny than usual for a mid-cap regional bank.
The most visible shift over the past fortnight has been on the analyst side, where the direction of travel is clearly downward on targets even if conviction has held. Cantor Fitzgerald trimmed its target to $41 from $45 on October 14, keeping a Neutral rating. Piper Sandler cut harder, dropping to $38 from $46 on October 7. TD Cowen, the only house with a Buy, also pulled back its target to $44 from $49 earlier in the month. The consensus mean price target now sits at $41.75 against a close of $35.36, implying roughly 18% upside on paper. That gap looks more cautious than bullish, three firms cutting in three weeks ahead of a print points to lowered expectations rather than a re-rating.
Short positioning has been creeping higher, though the absolute level keeps this in context. Short interest climbed about 13% over the past month to roughly 4.9% of free float, a noticeable build but not an extreme. Borrow remains very cheap at around 0.45%, and availability is generous, with shares available to borrow running at more than ten times the current short interest. There is no squeeze dynamic here. Options positioning leans the other way entirely: the put/call ratio is only 0.03, well below its 20-day average of 0.05, suggesting call-side interest has been dominant and investors are not paying for downside protection ahead of results. The ORTEX short score has edged up to 53.6 from 52.2 a week ago, a mild drift toward more bearish positioning without a strong directional signal.
The bull and bear cases divide sharply on credit quality and the rate environment. Bulls point to Q2 core EPS of $0.77 beating estimates, NIM expanding 6 basis points, and the bank guiding for NIM in the 3.30% to 3.35% range with low-teens loan growth, arguing the worst of the small-business credit cycle is likely behind it. Bears counter that 2026 EPS estimates have been cut to $2.80 from $3.01 and 2027 to $3.80 from $4.04, reflecting lower net interest income, reduced gain-on-sale revenue, and a higher provision in Q3. Non-guaranteed NPAs rose 23% quarter-on-quarter in Q2, and the stock has lost about 8% over the past month even as it clawed back 2% this week. The PE multiple has compressed to roughly 8.8x and price-to-book sits near 1.1x, both down meaningfully over 30 days. On factor scores, EPS momentum ranks in the 88th to 91st percentile on 30-day and 90-day windows, a genuine strength, but the forward earnings growth rank at 23 out of 100 reflects the cuts the Street has been making.
Ownership context is worth noting ahead of the print. T. Rowe Price holds about 14% of shares and reported a virtually unchanged position at end of September. Founder and CEO James Mahan holds around 13% but sold 100,000 shares in September at prices between $38.60 and $39.90, all under a pre-arranged 10b5-1 plan. The plan-based nature of those sales means they carry less informational weight than discretionary transactions, but the volume and price level, well above the current $35.36, is not a flattering comparison. Net insider sales over the past 90 days total nearly $6 million.
On the company's own balance sheet data, FDIC call reports show total assets and total deposits have each risen for nine consecutive quarters, reaching $16.5 billion and $15.2 billion respectively as of April 2026. The FDIC net income dataset against the company's reported quarterly figures is still too new to have a measured lead established, so that series is colour rather than a signal for the Q3 print.
The two recent earnings reactions on record were both positive: a 2.5% gain the day after Q2 results in July and a similar move five days out. Whether the reset in targets and the month-long price decline has already priced in a softer Q3, or whether the provision guidance and credit trajectory disappoint again, is the question the October 22 report will answer.
Stocks in this article
See the live data behind this article on ORTEX.
Open LOB on ORTEX →How this article was generated
- Generated
- 21 Oct 2026, 22:33
- Data as of
- 21 Oct 2026, 22:32
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.